Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
27. Juli 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
Aravive Achieves Second Development Milestone from 3D Medicines
15. Juli 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
07. Juli 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
24. Juni 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
Aravive Announces Three New Appointments to its Board of Directors
18. Mai 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the...
Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer
06. Mai 2021 07:00 ET
|
Aravive, Inc.
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancerFirst patient dosed in registrational Phase 3 trial...
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
27. April 2021 07:00 ET
|
Aravive, Inc.
Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the...
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
16. März 2021 07:00 ET
|
Aravive, Inc.
Initiated a registrational trial of AVB-500 in Platinum Resistant Ovarian Cancer in 1Q 2021First patient dosed in Phase 1b/2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma in 1Q 2021; On-track to...
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting
12. März 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b...
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
08. März 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its...